Survival time for myeloma patients nearly doubled since 2005
Over a 15-year period, the median survival time for people with myeloma has nearly doubled, increasing from 2.4 years for those diagnosed in 2005…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
NASCAR car makeover driving awareness of pediatric blood cancer
The advocacy organization Blood Cancer United has teamed up with motor oil company Valvoline Global and auto racing group Hendrick Motorsports to raise awareness…
FDA approves 2 biosimilar drugs for cancer-related bone problems
The U.S. Food and Drug Administration (FDA) has approved two new biosimilar drugs — versions of brand-name therapies that have no clinically meaningful differences compared…
Cell therapy CER-1236 put on FDA fast track as AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing to…
Chemical in cigarette smoke drives pancreatic cancer: Study
A chemical in cigarette smoke can increase the odds of developing pancreatic cancer by changing the immune system’s activity. That’s according to a new…
New strategy targets the ‘mesh’ around tumors to stop glioblastoma
Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…
Groups unite to raise gynecologic cancer awareness in September
September is Gynecologic Cancer Awareness Month, and advocacy organizations are hosting events, sharing information on social media, and raising funds to advance research.
Glioblastoma treatment combo shows promise in pilot study
A combination therapy for glioblastoma showed encouraging early results, with all five patients treated in a pilot study responding to it. Based on the data,…
Modeyso becomes 1st FDA-approved treatment for rare glioma
Jazz Pharmaceuticals said the U.S. Food and Drug Administration (FDA) granted accelerated approval to the weekly oral therapy dordaviprone, to be marketed under the brand…
Blood cancer therapy SGR-2921 discontinued after patient deaths
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
